X4 Pharmaceuticals (XFOR) Q3 2024 Earnings
XFOR·Reported November 13, 2024·Before market open
X4 Pharmaceuticals reported Q3 2024 revenue of $560.0K, missed analyst consensus of $1.0M by $457.6K. Diluted EPS came in at $-0.18, missed the $-0.17 consensus by $0.01.
Revenue
$560.0Kmissed by $457.6K
Consensus: $1.0MDiluted EPS
$-0.18missed by $0.01
Consensus: $-0.17
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about X4 Pharmaceuticals's Q3 2024 earnings report.
X4 Pharmaceuticals (XFOR) reported Q3 2024 earnings on November 13, 2024 before market open.
X4 Pharmaceuticals reported revenue of $560.0K and diluted EPS of $-0.18 for Q3 2024.
Revenue missed the consensus estimate of $1.0M by $457.6K. EPS missed the consensus estimate of $-0.17 by $0.01.
You can read the 10-Q periodic report (0001628280-24-047445) directly on SEC EDGAR. The filing index links above go to sec.gov.